Profile cover photo
Profile photo
Celltex Therapeutics
Celltex Therapeutics's posts

Post has attachment
Steering stem cell trafficking into pancreas reverses type 1 diabetes

Researchers at Brigham and Women’s Hospital, a Harvard-affiliated hospital, have been studying mesenchymal stem cells (MSCs) and have reportedly uncovered a way to enhance and prolong the cells’ therapeutic efforts in type 1 diabetes. While studying a preclinical trial of diabetic-prone mice, Harvard Medical School Professor Robert Sackstein and a team of researchers found that the intravenous administration of MSCs stifled pancreatic injuries by reducing the levels of sugar in the bloodstream of those mice without the need of insulin administration. Due to this finding, Sackstein and his team hypothesized that if more MSCs could be forced to populate inside the pancreatic islets, there is a higher chance of a complete reversal of diabetes. MSCs usually lack a key cell surface adhesion molecule called HCELL, which prevents MSCs from being directly inserted into pancreatic islets due to how fragile the pancreas is. However, when the researchers engineered an HCELL molecule to steer the MSCs toward the inflamed pancreas, the team found that these HCELL- bearing MSCs caused the cells to lodge into the pancreatic islets. This lodging resulted in the normalization of blood sugar levels, which in turn eliminated the need for insulin administration. Sackstein believes that this study is an important step in the use of mesenchymal stem cells in the treatment of type 1 diabetes and other immune–related issues.

Post has attachment
Stem Cell in Eye May Help Restore Vision Following Cornea Injury, Infection

A recent study posted in Science Transitional Medicine suggests that mesenchymal stem cells from a patient’s own eye may one day replace corneal transplants. Dr. Sayan Basu and his team of doctors in India have been studying mesenchymal corneal stem cells for over a decade and have found that these cells can regenerate wounded corneal cells in mice far more effectively than the limbus stem cells that have already been through a clinical trial. Researchers found that after 50,000 stem cells were applied to the eyes of mice, there was no evidence of inflammation or rejection four weeks later. Doctors are confident there is a very low risk of inflammation or rejection in a patient because the cells are taken directly from the patient and grown in the patient’s own serums. Researchers hope to begin clinical trials in the United States in the next 3 years and are confident that this procedure could help millions of people worldwide in need of corneal transplants.

Post has attachment
Pearland boy makes remarkable recovery via stem cells - Your Houston News: News
Wait while more posts are being loaded